Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, announced the pricing of its initial public offering of 13,800,000 shares of its common stock at a public offering price of US$16.00 per share. The gross proceeds to Talis from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Talis, are expected to be approximately US$220.8 million. In addition, Talis has granted the underwriters a 30-day option to purchase up to 2,070,000 additional shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.
Latham & Watkins LLP represents the underwriters in the transaction with a corporate deal team led by Bay Area partners Brian Cuneo and Miles Jennings, with associates Ken Hagan and Raul Gonzalez. Advice was also provided on FDA regulatory matters by Washington, D.C. partners John Manthei and Elizabeth Richards and Bay Area counsel Heather Deixler and Betty Pang, with associate Barrett Tenbarge; on intellectual property matters by Bay Area partner Chris Hazuka, with associate Brendan Haberle; on benefits and compensation matters by Bay Area partner Ashley Wagner; and on tax matters by Bay Area partner Grace Lee, with associate Amy Feinberg.